Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

bayer new zealand limited - ethinylestradiol 20ug; levonorgestrel 100ug - coated tablet - 20µg/100µg - active: ethinylestradiol 20ug levonorgestrel 100ug excipient: calcium carbonate glycerol glycol montanate iron oxide red iron oxide yellow lactose monohydrate macrogol 6000 magnesium stearate maize starch povidone   purified talc purified water starch sucrose titanium dioxide calcium carbonate glycol montanate lactose monohydrate macrogol 6000 magnesium stearate maize starch povidone   purified talc   sucrose - oral contraception

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

bayer new zealand limited - ethinylestradiol 0.03mg; levonorgestrel 0.15mg - tablet - active: ethinylestradiol 0.03mg levonorgestrel 0.15mg excipient: calcium carbonate glycerol glycol montanate iron oxide yellow lactose monohydrate macrogol 6000 magnesium stearate maize starch povidone   purified talc   sucrose titanium dioxide calcium carbonate glycol montanate lactose monohydrate macrogol 6000 magnesium stearate maize starch povidone   purified talc   sucrose - oral contraception

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

bayer new zealand limited - ethinylestradiol 0.05mg; levonorgestrel 0.125mg - tablet - active: ethinylestradiol 0.05mg levonorgestrel 0.125mg excipient: calcium carbonate glycerol wax e iron oxide yellow lactose monohydrate macrogol 6000 magnesium stearate maize starch povidone as polyvidone 25,000   purified talc   sucrose titanium dioxide calcium carbonate glycol montanate lactose monohydrate macrogol 6000 magnesium stearate maize starch povidone   purified talc   sucrose - oral contraception

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - ethinylestradiol 30ug; levonorgestrel 150ug; ethinylestradiol 30ug; levonorgestrel 150ug - tablet - 30mcg/150mcg - active: ethinylestradiol 30ug levonorgestrel 150ug excipient: calcium carbonate glycerol glycol/butylene glycol montanate iron oxide yellow lactose monohydrate macrogol 6000 magnesium stearate povidone   purified talc   purified water starch sucrose titanium dioxide calcium carbonate erythrosine montangylycol wax (wax e pharma) (dab) lactose monohydrate macrogol 6000 magnesium stearate ponceau 4r povidone   purified talc   starch sucrose active: ethinylestradiol 30ug levonorgestrel 150ug excipient: calcium carbonate carnauba wax white wax, polishing lactose monohydrate macrogol 6000 magnesium stearate povidone   purified talc   purified water starch sucrose calcium carbonate erythrosine montangylycol wax (wax e pharma) (dab) macrogol 6000 magnesium stearate ponceau 4r povidone purified talc starlac sucrose calcium carbonate erythrosine wax e pharma lactose macrogol 6000 magnesium stearate maize starch ponceau 4r povidone   purified talc   purified water sucrose - monofeme is indicated for prevention of pregnancy.

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

viatris limited - rosuvastatin calcium 10.396mg equivalent to rosuvastatin 10 mg - film coated tablet - 10 mg - active: rosuvastatin calcium 10.396mg equivalent to rosuvastatin 10 mg excipient: colloidal silicon dioxide crospovidone iron oxide red lactose monohydrate light magnesium oxide magnesium stearate microcrystalline cellulose opadry pink - rosuvastatin calcium is indicated to: · reduce elevated ldl-c, total cholesterol, triglycerides and to increase hdlcholesterol in patients with primary hypercholesterolemia (heterozygous familial and non familial) and mixed dyslipidaemia (fredrickson types iia and iib). rosuvastatin calcium also lowers apob, nonhdl-c, vldl-c, vldl-tg, the ldl-c/hdl-c, total c/hdl-c, nonhdl-c/hdl-c, apob/apoa-i ratios and increase apo-a-i in these populations. · treat isolated hypertriglyceridaemia (fredrickson type iv hyperlipidaemia). · reduce total cholesterol and ldl-c in patients with homozygous familial hypercholesterolemia, as an adjunct to diet and other lipid lowering treatments (e.g. ldl apheresis) or alone if such treatments are unavailable.

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

viatris limited - rosuvastatin calcium 20.792mg equivalent to rosuvastatin 20 mg - film coated tablet - 20 mg - active: rosuvastatin calcium 20.792mg equivalent to rosuvastatin 20 mg excipient: colloidal silicon dioxide crospovidone iron oxide red lactose monohydrate light magnesium oxide magnesium stearate microcrystalline cellulose opadry pink - rosuvastatin calcium is indicated to: · reduce elevated ldl-c, total cholesterol, triglycerides and to increase hdlcholesterol in patients with primary hypercholesterolemia (heterozygous familial and non familial) and mixed dyslipidaemia (fredrickson types iia and iib). rosuvastatin calcium also lowers apob, nonhdl-c, vldl-c, vldl-tg, the ldl-c/hdl-c, total c/hdl-c, nonhdl-c/hdl-c, apob/apoa-i ratios and increase apo-a-i in these populations. · treat isolated hypertriglyceridaemia (fredrickson type iv hyperlipidaemia). · reduce total cholesterol and ldl-c in patients with homozygous familial hypercholesterolemia, as an adjunct to diet and other lipid lowering treatments (e.g. ldl apheresis) or alone if such treatments are unavailable.

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

viatris limited - rosuvastatin calcium 41.584mg equivalent to rosuvastatin 40 mg - film coated tablet - 40 mg - active: rosuvastatin calcium 41.584mg equivalent to rosuvastatin 40 mg excipient: colloidal silicon dioxide crospovidone iron oxide red lactose monohydrate light magnesium oxide magnesium stearate microcrystalline cellulose opadry pink - rosuvastatin calcium is indicated to: · reduce elevated ldl-c, total cholesterol, triglycerides and to increase hdlcholesterol in patients with primary hypercholesterolemia (heterozygous familial and non familial) and mixed dyslipidaemia (fredrickson types iia and iib). rosuvastatin calcium also lowers apob, nonhdl-c, vldl-c, vldl-tg, the ldl-c/hdl-c, total c/hdl-c, nonhdl-c/hdl-c, apob/apoa-i ratios and increase apo-a-i in these populations. · treat isolated hypertriglyceridaemia (fredrickson type iv hyperlipidaemia). · reduce total cholesterol and ldl-c in patients with homozygous familial hypercholesterolemia, as an adjunct to diet and other lipid lowering treatments (e.g. ldl apheresis) or alone if such treatments are unavailable.

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

viatris limited - rosuvastatin calcium 5.198mg equivalent to rosuvastatin 5 mg - film coated tablet - 5 mg - active: rosuvastatin calcium 5.198mg equivalent to rosuvastatin 5 mg excipient: colloidal silicon dioxide crospovidone iron oxide red lactose monohydrate light magnesium oxide magnesium stearate microcrystalline cellulose opadry yellow - rosuvastatin calcium is indicated to: · reduce elevated ldl-c, total cholesterol, triglycerides and to increase hdlcholesterol in patients with primary hypercholesterolemia (heterozygous familial and non familial) and mixed dyslipidaemia (fredrickson types iia and iib). rosuvastatin calcium also lowers apob, nonhdl-c, vldl-c, vldl-tg, the ldl-c/hdl-c, total c/hdl-c, nonhdl-c/hdl-c, apob/apoa-i ratios and increase apo-a-i in these populations. · treat isolated hypertriglyceridaemia (fredrickson type iv hyperlipidaemia). · reduce total cholesterol and ldl-c in patients with homozygous familial hypercholesterolemia, as an adjunct to diet and other lipid lowering treatments (e.g. ldl apheresis) or alone if such treatments are unavailable.

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - ethinylestradiol 0.035mg (does not include an overage of aprox. 3%);  ; norethisterone 0.5mg;  ;   - tablet - active: ethinylestradiol 0.035mg (does not include an overage of aprox. 3%)   norethisterone 0.5mg     excipient: indigo carmine lactose monohydrate magnesium stearate maize starch povidone lactose lactose monohydrate magnesium stearate microcrystalline cellulose sunset yellow fcf as fd&c yellow lake - contraception.

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - ethinylestradiol 2.7mg (15µg/24h elution rate in-vivo);  ; etonogestrel 11.7mg (120µg/24h elution rate in-vivo);   - vaginal ring - 120mcg etonogestrel, 15mcg ethinylestradiol / 24h - active: ethinylestradiol 2.7mg (15µg/24h elution rate in-vivo)   etonogestrel 11.7mg (120µg/24h elution rate in-vivo)   excipient: evatane 1020 vn3 ethylene/vinyl acetate co-polymer evatane 28-25 ethylene/vinyl acetate co-polymer magnesium stearate - contraception.